This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nordion To Launch Improved Physician Tools For TheraSphere® Liver Cancer Treatment At SIR Annual Scientific Meeting 2012

Company will also present expert speakers and introduce new iPad app

OTTAWA, March 23, 2012 /PRNewswire/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will be attending the Society for Interventional Radiologists (SIR) Annual Scientific Meeting 2012, taking place March 24-29 in San Francisco. The company will introduce several new or updated physician education tools and resources for TheraSphere®, Nordion's Y-90 microsphere treatment for liver cancer.

"With more than 5,000 physicians, scientists and healthcare professionals in attendance, SIR represents one of the most important annual medical meetings Nordion attends," says Peter Covitz, Nordion Senior Vice President, Innovation. "SIR provides an opportunity to connect directly with our key users, share the latest information about TheraSphere, listen to feedback, and respond to questions firsthand."

Nordion representatives will be at Booth #1234 to talk about TheraSphere. The company will host two "Eat and Be Educated" learning sessions at the booth:

Sunday, March 25, 12:15pm How TheraSphere Y-90 Glass Microspheres Fits in Our Treatment Algorithm Matthew Johnson, MD Professor of Radiology and Surgery Indiana University School of Medicine Indianapolis, IN

Tuesday March 27, 12:15pm TheraSphere Multi-Vessel Delivery Siddharth Padia, MD Assistant Professor, Interventional Radiologist University of Washington - Harbourview Medical Center Seattle, WA

Each session will be followed by a Nordion presentation on how to start a TheraSphere program.

Other Nordion TheraSphere activities at SIR include:

  • Launch of the:
    • New custom dose feature in Europe and Canada*
    • Updated Treatment Window Illustrator tool to assist physicians with dose selection
    • New animated video demonstrating how TheraSphere works
  • Preview of the upcoming TheraSphere iPad app
  • Participation in SIR's Residents in Training program

* Nordion has filed a request with the Food and Drug Administration for approval of the custom dose feature in the United States.

About Th eraSphere TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive yttrium-90 ( Y-90). The product is injected by physicians into the artery of the patient's liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.

In the US, TheraSphere is used to treat patients with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and can be used as a bridge to surgery or transplantation in these patients.  It is also indicated for the treatment of HCC patients with portal vein thrombosis (PVT).  TheraSphere is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs